Pittsburgh, PA 15260
Developing new reaction technology for the rapid and efficient construction of therapeutically relevant compounds forms the cornerstone of our research program. Reaction development efforts focus primarily on devising metal-based catalytic protocols for executing stereoselective bond constructions. Our principle objective is the rapid and economical preparation of optically active small-molecule building blocks that relate directly to the complex stereochemical and structural motifs embedded in natural product target molecules.
- Bristol-Myers Squibb Foundation, Award for Synthetic Chemistry (2001)
- Eli Lilly & Co., Award for Synthetic Organic Chemistry (2002)
- Chancellorís Distinguished Research Award (2002)